Abbott Laboratories stock gains support from fresh earnings and guidance

Abbott Laboratories stock is trading around 110 dollars as investors digest double-digit revenue growth in the latest quarter and a raised 2026 earnings outlook.

Abbott Laboratories (ISIN US0028241000) stock is trading near 110.5 USD as of September 3, 2026, after investors reacted to the company’s latest earnings beat and updated 2026 guidance showing continued double-digit growth in its healthcare portfolio.

Latest earnings beat and outlook

Abbott Laboratories reported earnings per share of 1.31 USD for its most recent quarter, released on July 16, 2026, exceeding the consensus estimate of 1.28 USD by 0.03 USD according to data compiled by MarketBeat. The same overview notes that quarterly revenue reached 12.59 billion USD, slightly above analyst expectations of 12.52 billion USD.

That revenue figure for the July 16, 2026 report represents a 13.0% increase compared with the same quarter a year earlier, highlighting that Abbott Laboratories is growing faster than many large-cap healthcare peers. MarketBeat data also shows the company generated a return on equity of 17.69% and a net margin of 11.65% in that quarter, underlining a combination of solid profitability and efficient use of capital.

Guidance, consensus and cash flow trends

On the back of those results, Abbott Laboratories has issued guidance for the third quarter of 2026 in a range of 1.38 to 1.46 USD earnings per share and for the full fiscal year 2026 in a range of 5.45 to 5.60 USD EPS, according to the same MarketBeat filings from September 3, 2026. The guidance table suggests that analysts on average expect 5.52 USD EPS for the current fiscal year, placing the consensus toward the middle of management’s range.

A separate consensus snapshot from Zacks indicates that analysts are projecting earnings of 1.43 USD per share and revenue of 12.91 billion USD for the upcoming quarter, implying expected year-over-year growth of 10% in EPS and 13.52% in revenue. The Zacks-based article further cites full-year consensus estimates of 5.52 USD EPS and 50.32 billion USD revenue for Abbott Laboratories, representing forecast increases of 7.18% and 13.51% respectively compared with the prior year.

From a balance-sheet perspective, Abbott Labs reported 110.4 billion USD in total assets in the first quarter of 2026, up 35.6% from the same quarter a year earlier according to StockTitan’s compilation of SEC filings. The balance-sheet overview shows that this expansion in assets has been accompanied by improving operating metrics and reflects investments in diagnostics, medical devices and nutrition businesses.

Cash generation remains a key pillar of the Abbott Laboratories investment case. Over the trailing 12 months from the second quarter of fiscal 2025 through the first quarter of fiscal 2026, Abbott Labs generated 7.4 billion USD in free cash flow, according to another StockTitan analysis of company filings. That same dataset notes that free cash flow in the first quarter of 2026 stood at 916.0 million USD, which was 1.8% lower than in the corresponding quarter a year earlier, suggesting a slight normalization after particularly strong prior-year cash generation.

Dividend, institutional interest and technical view

Abbott Laboratories continues to return cash to shareholders through dividends. Stockholders of record on July 15, 2026 received a quarterly dividend of 0.63 USD per share, which equates to an annualized dividend of 2.52 USD and a yield of about 2.3% at current price levels, based on figures cited in MarketBeat filings dated September 3, 2026. The same summary indicates that analysts classify Abbott Laboratories as a moderate buy, with a consensus target price of 119.50 USD, implying upside of roughly 8% from the 110.5 USD area.

Institutional investors have been active in Abbott Laboratories stock in recent filings. MarketBeat reports that several asset managers, including Triton Financial Group Inc. and Jefferies Financial Group Inc., disclosed new or expanded positions in Abbott shares in early September 2026. One Jefferies-related filing describes a 978,000 USD position, while another MarketBeat alert covers a 72.66 million USD stake taken by Man Group plc, underlining sustained institutional confidence in the stock’s prospects.

From a technical perspective, multiple same-day data snapshots show Abbott Laboratories stock opening at 110.52 USD on September 3, 2026 and trading near 110.5 USD during the session on the New York Stock Exchange. An institutional filing uses the 110.52 USD opening level for its valuation references, while an Indian stock portal quoting NYSE data reports a recent close at 110.43 USD with an intraday high of 112.20 USD and a low of 109.00 USD as of September 3, 2026. The Dhan quote page suggests that the share price has risen about 1.38% in the latest session, indicating that investors are rewarding the company’s guidance and earnings execution.

Diagnostics and devices in everyday use

Beyond the headline numbers, Abbott Laboratories is well known for healthcare products that many patients and physicians use daily. One representative area is its continuous glucose monitoring systems, which contribute a meaningful share to the company’s diagnostics and medical devices revenue and help underpin the double-digit growth trajectory seen in recent quarters.

Stock level and investor perspective

Abbott Laboratories stock is quoted at about 110.5 USD on the New York Stock Exchange as of September 3, 2026, with recent intraday trading between 109.00 USD and 112.20 USD. For retail investors, the combination of mid-single-digit dividend yield, high-teens return on equity and guided earnings growth in the high single to low double digits makes the stock a prominent name in global healthcare portfolios.

Abbott Laboratories stock facts

• Company: Abbott Laboratories Inc.
• ISIN: US0028241000
• Ticker: ABT
• Trading venue: NYSE
• Price (as of September 3, 2026): 110.50 USD
• Market capitalization: 190,000,000,000 USD (as of September 3, 2026)
• Sector / Industry: Health Care Equipment and Services
• Index membership: S&P 500